Global ovarian cancer drugs market was valued US$ 1.2 Bn in 2017 and is expected to reach US$ 4.6 Bn by 2026, at a CAGR of 18.29 % during a forecast period.
Global Ovarian Cancer Drugs Market
Ovarian Cancer begins in the female organs and that produce eggs i.e. ovaries. Ovarian cancer generally has no specific symptoms in the early stages. Later stages are associated with symptoms, but they can be non-specific such as loss of appetite and weight loss, thus the occurrence of ovarian cancer is increased.
The growing geriatric population of women, increase in ovarian cancer cases, and ease of use of new drugs and therapies, the rise in healthcare expenditure are expected to boost the growth of ovarian cancer drugs market. Increased government funding is also propelling the growth of the market. The lack of accurate diagnostic techniques for ovarian cancer in the early stages can also have a negative impact on the global ovarian cancer market.
Carboplatin is leading the market in chemotherapy drugs due to it is more used in developing the region. Carboplatin has much less serious side effects. Carboplatin is a chemotherapy medication used to treat a number of forms of cancer includes ovarian cancer, lung cancer, head and neck cancer, brain cancer, and neuroblastoma. It is used through injection into a vein. Some common side effects of carboplatin contain nausea, vomiting, numbness and tingling of extremities, ear infection, pain, weakness, allergic reactions, and hair loss.
North America is leading the market owing to the growing incidence of ovarian cancer in the region. The growing population of elderly women (55-64 years) is leading the growth of the North America region in ovarian cancer drugs market. In the Asia Pacific, India and China are the fastest developing countries owing to the growing healthcare expenditure in these regions, along with rising government funding and increasing target patient pool.
Key player operating in the global ovarian cancer drugs market are Bristol Myers Squibb Company, Eli Lilly and Company, GlaxosmithklinePlc, Janssen Pharmaceuticals, Inc., Kazia Therapeutics Ltd, Genentech Inc., Astra Zeneca Boehringer Ingelheim, and F. Hoffman-La Roche Ltd, among others.
The report covers a comprehensive study of major market drivers, restrains, opportunities, challenges, PESTEL, Porters, SWOT, and technological forecasting in the market.
The Scope of Global Ovarian Cancer Drugs Market:
Global Ovarian Cancer Drugs Market, by Chemotherapy Drugs:
Global Ovarian Cancer Drugs Market, by End User:
• Ambulatory Surgical Centers
• Other End Users
Global Ovarian Cancer Drugs Market, by Region:
• North America
• South America
• Middle East & Africa
Key Player Operating In the Global Ovarian Cancer Drugs Market:
• Bristol Myers Squibb Company
• Eli Lilly and Company
• Janssen Pharmaceuticals, Inc.
• Kazia Therapeutics Ltd
• Genentech Inc.
• Astra Zeneca Boehringer Ingelheim
• F. Hoffman-La Roche Ltd
This Report Is Submitted By Maximize Market Research
Customization of the report:
Maximize Market Research provides free personalized of reports as per your demand. This report can be personalized to meet your requirements. Get in touch with us and our sales team will guarantee provide you to get a report that suits your necessities.
About Maximize Market Research:
Maximize Market Research provides B2B and B2C research on 20,000 high growth emerging opportunities & technologies as well as threats to the companies across the Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.
Name: Lumawant Godage
Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.
Email: [email protected]
Address: Maharashtra 411051, India.